A new strategy of molecular targeting therapy for ovarian clear cell adenocinoma using transforming growth factor-betal(TGFβ1)

转化生长因子-β1（TGFβ1）分子靶向治疗卵巢透明细胞腺瘤的新策略

• 批准号: 18591850
• 负责人: KOMIYAMA Shin-ichi
• 金额: $ 2.49万
• 依托单位: Fujita Health University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2006
• 资助国家: 日本
• 起止时间: 2006 至 2007
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-18591850/
• 关键词: TGFβ1; ovarian clear cell adenocarcinoma; molecular targeting therapy; anti tumor effect; RMG-1

We studied a basic research for a new molecular targeting therapy for ovarian clear cell adenocarcinoma using transforming growth factor-beta 1 (TGFβ1). Several cell lines of human ovarian clear cell adenocarcinoma (RMG-1, RMG-2, and MO were demonstrated growth inhibition, G1 arrest, and invasion inhibition by TGFBI in vitro. RMG-1 expressed p57 mRNA and PAI-1 mRNA transcribed by TGFf31, dose-dependently. On the other hand, MIVIP2 protein expression was suppressed. Then xenograft models of RMG-1 were created in SCID mice, and tumor growth was assessed from the wet weight and the BrdU uptake. In tumor-bearing mice, the tumor weight and BrdU uptake were both lower when they were treated by TGFβ1. Furthermore, TGFβ1 combined several cytotoxic drugs (paclitaxel, SN-38, and CDDP) demonstrated growth inhibition additively for RMG-1 in vitro.

我们研究了转化生长因子-β1(转化生长因子-β1，β-1)分子靶向治疗卵巢透明细胞腺癌的基础研究。几种人卵巢透明细胞腺癌细胞(RMG-1、RMG-2和MO)在体外均表现出生长抑制、G1期停滞和侵袭抑制。RMG-1表达由TGFf31转录的p57mRNA和PAI-1mRNA，呈剂量依赖关系。另一方面，MIVIP2蛋白表达受到抑制。然后在SCID小鼠体内建立RMG-1异种移植模型，通过湿重和BrdU摄取量来评估肿瘤的生长。在荷瘤小鼠中，转化生长因子β1处理的肿瘤重量和对BrdU的摄取量都较低。此外，转化生长因子β1联合几种细胞毒药物(紫杉醇、SN-38和顺铂)在体外对RMG-1具有明显的生长抑制作用。

项目成果

Papillary serous carcinoma of the peritoneum with paraaortic lymph node metastasis despite minimal intraperitoneal involvement:a case report

腹膜乳头状浆液性癌伴主动脉旁淋巴结转移，尽管腹膜内受累极少：一例报告

• 发表时间: 2006
• 期刊: Acta cytologica 50
• 作者: Shin-ichi Komiyama;et. al.
• 通讯作者: et. al.

進行上皮性卵巣癌におけるTGFβ発現は生物学的悪性度や薬剤感受性を推定する新たなbiomarkerになりうるか?

晚期上皮性卵巢癌中TGFβ的表达能否成为评估生物恶性程度和药物敏感性的新生物标志物？

• 发表时间: 2007
• 作者: 小宮山 慎一;他
• 通讯作者: 他

Is mRNA expression of TGFβ1 is related with the biological significance and drug sensitivity of anti-cancer agents in advanced ovarian cancer?

TGFβ1 mRNA表达与晚期卵巢癌抗癌药物的生物学意义和药物敏感性相关吗？

• 发表时间: 2007
• 作者: Komiyama S;et. al.
• 通讯作者: et. al.

産婦人科 専門医に聞く最新の臨床

妇产科专家最新临床资讯

• 发表时间: 2007
• 作者: 小宮山 慎一;他
• 通讯作者: 他

合成ステロイドホルモン -抗ステロイドホルモン薬の臨床応用-

合成类固醇激素-抗类固醇激素药物的临床应用-

• 发表时间: 2007
• 期刊: 日本臨床 66
• 作者: 小宮山 慎一;他
• 通讯作者: 他